Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FENSZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, represents a discrete purchase of pharmaceutical products and medical consumables to support Department of Defense healthcare operations. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. As the prime contractor, DMS Pharmaceutical Group will deliver from its comprehensive product portfolio, which includes branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR within the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded in November 2025 with a ceiling value of $499,999,999 and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion government-wide acquisition strategy designed to establish multiple regional prime vendor contractors that serve as critical pharmaceutical suppliers for military healthcare facilities worldwide. This particular delivery order exemplifies the recurring pharmaceutical supply needs fulfilled through the broader program structure, enabling DLA to efficiently procure specialized medications and medical consumables to support global Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DU26FENSZ?
SPE2DU26FENSZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DU26FENSZ worth?
The government has obligated $4,255 on SPE2DU26FENSZ.
Is contract SPE2DU26FENSZ an order under another contract?
Yes. SPE2DU26FENSZ is a delivery order under SPE2DU25D9420, an indefinite delivery contract.
Was contract SPE2DU26FENSZ competed?
The extent of competition for SPE2DU26FENSZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award